Literature DB >> 22451952

Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. 2003.

Lawrence A Yannuzzi, Jason S Slakter, Nicole E Gross, Richard F Spaide, Danielle L L Costa, Sheau J Huang, James M Klancnik, Alexander Aizman.   

Abstract

BACKGROUND: Most patients with central serous chorioretinopathy (CSC) have spontaneous resolution of exudative macular detachments and a good visual prognosis. Patients with CSC have a primary choroidal hyperpermeability problem evident as multifocal areas of hyperpermeability during indocyanine green (ICG) angiography. A small percentage of patients develop chronic or progressive disease with widespread decompensation of the retinal pigment epithelium and severe vision loss. There is no known treatment for this variant of the disorder.
PURPOSE: To study ICG-guided photodynamic therapy (PDT) with verteporfin as a potential treatment for patients with chronic CSC.
METHODS: Twenty eyes of 15 patients were studied with fluorescein angiography, optical coherence tomography, and ICG angiography to diagnose the maculopathy, monitor the detachments, and localize the choroidal hyperpermeability of the disorder. PDT with ICG guidance was applied to areas of choroidal hyperpermeability, and the patients were observed to determine the anatomic and functional outcomes.
RESULTS: Photodynamic therapy guided by ICG was associated with complete resolution of exudative macular detachments in 12 patients and incomplete resolution in the remaining eight eyes. The vision improved in six eyes and remained unchanged in 14 eyes during a mean follow-up of 6.8 months. Six weeks after treatment, the mean visual acuity improved by 0.55 lines, an amount that was marginally significant. There was a significant inverse correlation between the baseline visual acuity and the amount of improvement in acuity at 6 weeks. No patient had any treatment-related side effects.
CONCLUSIONS: Indocyanine green angiography-guided PDT with verteporfin seems to aid in the resolution of exudative detachments in patients with chronic CSC. This treatment was associated with a rapid reduction in subretinal fluid and improvement in visual acuity. Although the follow-up time and number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451952     DOI: 10.1097/iae.0b013e31823f99a9

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

2.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

Review 3.  Pachychoroid disease spectrum: review article.

Authors:  Thiago José Muniz Machado Mazzeo; Henrique Monteiro Leber; Allan Gomes da Silva; Raimunda Cristina Mendonça Freire; Gabriel Castilho Sandoval Barbosa; Guilherme Garcia Criado; Gabriel Almeida Veiga Jacob; Cleide Guimarães Machado; André Marcelo Vieira Gomes
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-10-14       Impact factor: 3.117

4.  Is myopia a protective factor against central serous chorioretinopathy?

Authors:  George J Manayath; Saurabh Arora; Hardik Parikh; Parag K Shah; Sarvesh Tiwari; Venkatapathy Narendran
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

5.  Atypical chronic central serous chorioretinopathy with cystoid macular edema: Therapeutic response to medical and laser therapy.

Authors:  Jiun L Do; Lisa C Olmos de Koo; Hossein Ameri
Journal:  J Curr Ophthalmol       Date:  2017-02-17

6.  Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.

Authors:  Takehito Iwase; Hirotaka Yokouchi; Masayasu Kitahashi; Mariko Kubota-Taniai; Takayuki Baba; Shuichi Yamamoto
Journal:  Biomed Res Int       Date:  2020-08-17       Impact factor: 3.411

7.  Superficial Retinal Microvasculature and Choriocapillaris Alterations after Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.

Authors:  Morteza Entezari; Iman Ansari; Alireza Ramezani; Humayoun Nikkhah; Parisa Mohammadi; Bahar Kheiri
Journal:  J Ophthalmol       Date:  2022-07-31       Impact factor: 1.974

Review 8.  Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy.

Authors:  Shaheen P Karim; Ron A Adelman
Journal:  Clin Ophthalmol       Date:  2013-09-19

9.  Erythrocyte-derived photo-theranostic agents: hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications.

Authors:  Baharak Bahmani; Danielle Bacon; Bahman Anvari
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.